[1]谭中宝,刘璐,郭金和,等.32P粒子植入对正常肝组织损伤及体内代谢的实验研究[J].介入放射学杂志,2010,(04):309.
 TAN Zhongbao,LIU Lu,GUO Jinhe,et al.The metabolism of 32P-CP-PLLA seed implanted in the liver and its damage to the normal liver tissue:a study in the experimental dogs[J].journal interventional radiology,2010,(04):309.
点击复制

32 P粒子植入对正常肝组织损伤及体内代谢的实验研究()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2010年04期
页码:
309
栏目:
实验研究
出版日期:
2010-04-15

文章信息/Info

Title:
The metabolism of 32 P-CP-PLLA seed implanted in the liver and its damage to the normal liver tissue:a study in the experimental dogs
作者:
谭中宝刘璐郭金和
21009南京东南大学附属中大医院介入科(谭中宝、郭金和、朱光宇、滕皋军);东南大学临床医学院核医学技术研究所(刘璐、聂琦、高海林)
Author(s):
TAN Zhong-baoLIU LuGUO Jin-heZHU Guang-yuWANG Fu-anNIE Qi GAO Hai-linTENG Gao-jun
Affiliated Zhongda Hospital,Southeast University,Nanjing210009,China
关键词:
32 P-CP-PLLA粒子内放射治疗间质靶向定位安全性
分类号:
R730.55
文献标志码:
B
摘要:
目的观察 32 P-磷酸铬-聚L-乳酸( 32 P-CP-PLLA)粒子对正常犬肝组织损伤效应,及其体内代谢和缓释效应。方法Beagle犬12只,随机分为4个剂量组,A组185MBq、B组370MBq、C组740MBq,D组为空白对照假手术组。采用开腹将 32 P-CP-PLLA粒子植入犬肝脏内,3个月后处死。术前及处死前均行CT扫描,术前及术后1、2、4、8、12周进行血象及血清生化检查,B、C两组各选1只于代谢笼内饲养,术后1个月内每24h测量粪便及尿液放射性计数率值(cpm),术后1、2、4、8、12周每组选1只犬行肝穿刺及SPECT韧致辐射显像,处死时行病理学检查。结果所有实验犬血象及血生化各项指标未见明显异常;术后30d的排泄物放射性检查表明粒子在体内缓慢释放;尿、粪排出的放射性计数累积百分率分别为6.34%和11.64%;SPECT显像示无粒子移位现象;3个月后解剖发现粒子体积变小、质地松脆,CT、大体标本和病理学检查结果均发现随着剂量增大,肝脏内粒子植入部位毁损灶增大。32 P-CP-PLLA粒子造成的局部肝损伤呈一球形灶:纤维化组织包绕坏死灶,外周可见一圈水肿带。结论 32 P-CP-PLLA粒子植入犬肝脏后对肝组织内的损伤是局限的,不会造成全身的不良反应,在体内无脏器迁移,并呈现缓慢释放,显示出良好体内稳定性、靶向定位性和安全性。

参考文献/References:

[1]Siegel HJ ,Luck JV Jr,Siegel ME,et al.Hemarthrosis and synovitis associated with hemophilia:clinical use of P-32chromic phosphate synoviorthesis for treatment [J].Radiology,1994,190:257-261.
[2]Liu L,Feng GS,Gao H,et al.Chromic-P32phosphatetreatment of implanted pancreatic carcinoma :Mechanism involved[J].WJG,2005,11:2101-2108.
[3]Firusian N,Dempke W.An early phaseⅡstudy of intratumoral P-32chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases[J].Cancer1999,85:980-987.
[4]El-Serag HB,Rudolph KL.Hepatocellular carcinoma :epide-miology and molecular carcinogenesis[J].Gastroenterology,2007,132:2557-2576.
[5]Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma [J].Lancet,2003,362:1907-1917.
[6]陈自谦,杨利,杨熙章,等.肝癌介入治疗现状与进展[J].介入放射学杂志,2008,17:223-227.
[7]McCready VR,Cornes P.The potential of intratumoural unsealed radioactive source therapy[J].Eur J Nucl Med,2001,28:567-569.
[8]Daozhen C,Lu L,Guansheng T,et al.Preventing and treating lymphatic minute metastasis with 32 P-chromic phosphate during an operation[J].Cancer Biotherapy&Radiopharmaceuticals,2007,22:24-32.
[9]Guo JH,Teng GJ ,Zhu GY,et al.Self-expandable stent loaded with 125 I seeds:feasibility and safety in a rabbit mode[J].Eur J Radiol,2007,61:356-361.
[10]郭金和,滕皋军,朱光宇,等. 125 I放射粒子在肿瘤介入治疗中的应用[J].介入放射学杂志,2005,14:613-617.
[11]李斌,曹喜才.放射性核素介入治疗肝癌的评价[J].介入放射学杂志,2004,13:276-278.
[12]Order S,Siegel J,Lustig R,et al.A new method for delivering radioactive cytotoxic agents in solid cancers[J].International Journal of Radiation Oncology,Biology,Physics,1994,30:715-720.
[13]Zhang K,Susan LE,Loong SL,et al.Complete tumor response following intratumoral 32 PBioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice[J].Clin Cancer Res,2005,11:7532-7537.
[14]Anthony Soon-Whatt Goh.A novel approach to brachy-therapy in hepatocellular carcinoma using a phosphorous32(32P)brachytherapy delivery device-a first in man study[J].Int J Radiat Oncol Biol.Phys,2007,67:786-792.
[15]邵国强,王自正,刘璐,等. 32 P-磷酸铬-聚L-乳酸缓释粒子体内外释出率及体内生物分布的初步研究[J].中华核医学杂志,2009,29:189-193.
[16]聂琦,刘璐,黄培林,等.胶体 32 P-磷酸铬间质给药对犬累积损伤效应的研究[J].中华放射医学与防护杂志,2010,30:7-14.

备注/Memo

备注/Memo:
收稿日期:2009-10-14
基金项目:国家高技术研究发展计划(863计划)(2007AA02Z471)
更新日期/Last Update: 2010-04-15